69 results about "Ganoderic acid" patented technology

The invention discloses glycosylated ganoderic acid with a chemical structural formula shown in the specification, the compound can effectively improve H2O2-induced cellular morphological change, remarkably reduce generation of reactive oxygen species (ROS) and reduce accumulation of beta-galactosidase in senescent cells, and in addition, cell immunoblotting analysis shows that the compound can be used for preparing glycosylated ganoderic acid. The glycosylated ganoderic acid can significantly down-regulate the expression of H2O2-induced senescence marker proteins p16 and p21, and experimental results prove that the glycosylated ganoderic acid has potential in the aspect of reversing cell senescence, provides a new candidate compound for the development of anti-senescence drugs, and shows a wide application prospect; # imgabs0 #

The invention discloses application of a gene GlZn2Cys661 in regulation and control of synthesis of ganoderic acid. The nucleotide sequence of the gene GlZn2Cys661 is as shown in SEQ ID NO. 1. The gene expression is regulated and controlled by constructing an overexpression or silent vector, so that the synthesis of the ganoderic acid is promoted or inhibited, and an effective method is provided for regulating and controlling the yield of the ganoderic acid. The invention relates to the technical field of bioengineering, and discloses an application of a gene GlZn2Cys661 in regulation and control of ganoderic acid synthesis. The invention provides a key gene target and a core engineering strain for efficiently producing ganoderic acid through a metabolic engineering means, and has important application value.

The invention belongs to the technical field of biological medicines, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing and / or treating biliary atresia. The new application of ganoderic acid A in preparation of drugs for preventing and / or treating biliary atresia is found for the first time. The method comprises the following steps: within 24 hours after a BALB / c newborn mouse is born, inducing the formation of BA by intraperitoneal injection of RRV, and from the second day after intraperitoneal injection of RRV, carrying out intraperitoneal injection of Ganoderic Acid A on the mouse every day until the twelfth day, it can be observed that the survival time of BA mice treated by the Ganoderma Acid A is prolonged, the weight loss is obviously improved, the jaundice symptom is relieved, the liver function index is obviously improved, the infiltration number of inflammatory cells around the intrahepatic bile duct is obviously reduced, and the liver bile duct injury is relieved. The invention provides a new potential target and a treatment strategy for treatment of BA, and has potential clinical treatment significance.

The invention discloses a Ganoderma lucidum engineering strain delta W2 after gene editing, a preparation method of the Ganoderma lucidum engineering strain delta W2, and a ganoderic acid compound 3alpha, 22alpha-diacetoxylanost-8, 24-dien-26-oic acid generated by fermentation of the Ganoderma lucidum engineering strain delta W2, and the chemical structural formula of the ganoderic acid compound is shown in the specification. The compound can effectively improve NO release of LPS-induced macrophages RAW264.7 and inhibit release of inflammatory factors TNF-alpha and IL-6, and has a wide application prospect in addition to anti-inflammatory drugs, health-care functional foods or cosmetics. # imgabs0 #

The invention provides an application of a ganoderma lucidum transcription factor yabby1 in regulating and controlling the transcriptional activity of a ganoderic acid synthetic gene SQS and a method, and belongs to the field of gene engineering. The nucleotide sequence of the yabby1 gene provided by the invention is as shown in SEQ ID NO. 1, and the amino acid sequence of the yabby1 gene is as shown in SEQ ID NO. 2; the ganoderma lucidum transcription factor yabby1 gene and the ganoderma lucidum SQS gene are constructed on a recombinant vector and are introduced into cells, so that the expression of the ganoderma lucidum SQS gene can be activated, and the content of ganoderic acid in ganoderma lucidum can be increased.

The invention relates to the technical field of ganoderic acid, in particular to a preparation and structure confirmation method and device of high-purity ganoderic acid, and the technical scheme is that the device comprises a reaction kettle, a hopper, a radiator and a heater are respectively mounted in the reaction kettle, and a high-speed countercurrent chromatograph is mounted on the bottom end surface of the hopper through a discharge pipe; a crusher is mounted on the reaction kettle through a mounting frame, a screen is mounted in the crusher, a driving motor is mounted on the screen, and a crushing wheel is arranged on an output shaft of the driving motor; a mounting disc is mounted on the reaction kettle, a high-pressure pump and a carbon dioxide steel cylinder are respectively mounted on the mounting disc, and feeding pipes are respectively mounted on the top end surface of the reaction kettle in an embedded manner and are communicated with the reaction kettle. According to the method, the ganoderic acid quality problem during ganoderic acid detection is solved, the ganoderic acid can be optimally prepared, and the influence of internal temperature and pressure difference on the quality of the prepared ganoderic acid is avoided.

The invention discloses ganoderic acid mass production and application based on cytochrome P450 enzyme CYP512W6, the cytochrome P450 enzyme CYP512W6 in ganoderma lucidum is converted into a corresponding saccharomyces cerevisiae strain for heterologous expression, and three kinds of ganoderic acid, namely TLTOA, 3 beta-TLTOA and DLDOA, are obtained after fermentation. The invention provides a new implementation mode for heterologous biosynthesis of ganoderic acid in saccharomyces cerevisiae.

The invention provides a ganoderma lucidum transcription factor Zn-8, a derivative of the ganoderma lucidum transcription factor Zn-8, application of the ganoderma lucidum transcription factor Zn-8 in synthesis of ganoderic acid and a method, and belongs to the field of genetic engineering. The nucleotide sequence of the ganoderma lucidum transcription factor Zn-8 provided by the invention is as shown in SEQ ID NO.1, and the amino acid sequence is as shown in SEQ ID NO.2; the ganoderma lucidum transcription factor Zn-8 gene, the ganoderma lucidum SQS gene and the ganoderma lucidum LSS gene are constructed on a recombinant vector and are introduced into cells, so that the expression of the ganoderma lucidum SQS gene and the ganoderma lucidum LSS gene can be activated, and the content of ganoderic acid in ganoderma lucidum is increased.

The invention discloses a culture medium composition for culturing dendritic cells and a culture method, and belongs to the field of biological medicines. Aiming at the problems of long induced differentiation period and low purity of the existing DC, the invention provides the culture medium composition for culturing the dendritic cells, the culture medium composition comprises a basic culture medium, an induction culture medium, a maturation culture medium and a function strengthening culture medium, the induction culture medium comprises the basic culture medium, and the maturation culture medium comprises a mature culture medium and a function strengthening culture medium; the GM-CSF, the IL-4, the astragalus polysaccharide and the rapamycin are added into the basic culture medium; the mature culture medium comprises a basic culture medium, and TNF-alpha, IFN-gamma, ganoderic acid and Poly (I: C) which are added into the basic culture medium, the function-enhanced culture medium comprises a basic culture medium, and IL-10, IL-12 and vitamin D3 which are added into the basic culture medium. The culture medium in each stage is combined with the synergistic effect of specific cell factors and natural plant extracts, so that high-purity and high-activity induction of the DC is realized, and the DC has the capability of resisting tumor microenvironment inhibition.

This barrier function enhancer, this occludin mRNA expression promoter, this claudin-1 mRNA expression promoter, this claudin-4 mRNA expression promoter, this tight junction protein-1 mRNA expression promoter, and this tight junction protein-2 mRNA expression promoter contain ganoderic acid as an active ingredient.

The invention discloses an NKT cell, a culture medium and a culture method thereof, and relates to the technical field of cell culture, the NKT cell comprises a basal culture medium, a cell factor combination, a plant extract compound, a metabolism regulator and an antioxidant; wherein the plant extract compound is prepared from astragalus polysaccharide, ganoderic acid, tea polyphenol, asiaticoside and notoginsenoside R1, and the mass ratio of the astragalus polysaccharide to the ganoderic acid to the tea polyphenol to the asiaticoside to the notoginsenoside R1 is (3 to 5) to (1 to 2) to 1 to (0.5 to 1) to (0.5 to 1). According to the NKT cell, the culture medium and the culture method of the NKT cell, through the synergistic effect of the six-membered plant extract compound, the expression of cyclin is promoted, the G1 / S phase conversion is accelerated, and the cell amplification amount is remarkably increased; the ratio of plant extracts and high astragalus polysaccharide are dynamically adjusted, so that cell proliferation and induced differentiation of high ganoderic acid are promoted, cells are forced to turn to efficient-productivity oxidative phosphorylation metabolism in cooperation with 2-deoxyglucose, and the cell multiplication time is shortened.

The application discloses Jianyang capsule fingerprint spectrum and a construction method and application thereof, and relates to the technical field of quality detection. The construction method of the Jianyang capsule fingerprint spectrum comprises the following steps: preparing a control solution by using ginsenoside Rg1, ginsenoside Rb1, notoginsenoside R1, ganoderic acid A, primulaverin and 2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside; preparing a test solution by using powders of Jianyang capsules of different batches; and performing high performance liquid chromatography analysis on the control solution and the test solution respectively to generate the Jianyang capsule fingerprint spectrum. The main peak and each chromatographic peak of the Jianyang capsule fingerprint spectrum obtained by the application are well separated, the Jianyang capsule fingerprint spectrum is applied to quality control detection of Jianyang capsules, the quality of the products can be comprehensively monitored, the consistency, controllability and stability of the product quality are ensured, and therefore, the quality of the Jianyang capsule products can be more comprehensively monitored.

The invention relates to a method for heterologously producing ganoderic acid, which comprises the following steps: respectively transforming candidate oxidase, candidate reductase and candidate acetyltransferase into corresponding saccharomyces cerevisiae strains for heterologously expressing, and screening the transformed strains through intracellular fermentation or whole-cell catalysis to obtain codon-optimized AfuSDR and CsSDR capable of catalyzing oxidization of hydroxyl of a ganoderma triterpene skeleton C3, the method comprises the following steps of: performing independent expression or combined expression on reductases AKR1C2, AKR1C4 and FusC1 which are optimized by codons and are used for catalyzing C3 keto reduction and acetyltransferase BsAT which is optimized by codons and is used for catalyzing C3 hydroxyl acetylation, so as to realize heterologous biosynthesis of ganoderic acid TR (GA-TR), gibberellic acid Ja (GA-Ja) and ganoderic acid Mf (GA-Mf).

The invention discloses an application of ganoderic acid A in preparation of a product for preventing and / or treating a non-alcoholic fatty liver disease. The ganoderic acid A can regulate bile acid reabsorption of C57BL / 6J mice induced by high fat diet and reduce absorption of triglyceride and cholesterol. The ganoderic acid A can also enhance expression of a key enzyme cholesterol 7alpha-hydroxylase gene for liver cholesterol decomposition, so that liver cholesterol is promoted to be converted into bile acid, and accumulation of liver cholesterol is relieved. The ganoderic acid A has remarkable prevention and improvement effects on the non-alcoholic fatty liver disease induced by high fat diet by regulating bile acid metabolism, inhibiting lipid absorption and relieving liver lipid accumulation. Therefore, the ganoderic acid A can be used as a health-care product, a functional product or a medicine for preventing and treating the non-alcoholic fatty liver disease.

The invention belongs to the technical field of disease drug treatment, and particularly relates to application of a CLK2 inhibitor in preparation of a drug for treating IgA nephropathy. The CLK2 inhibitor (such as ganoderic acid A methyl ester) can be used for remarkably reducing the levels of 24h UTP, 24h mAlb, BUN and Scr of an IgA nephropathy model and IGA deposition in glomerulus, so that the aim of effectively treating the IgA nephropathy is fulfilled.

The invention discloses synthesis and application of a ganoderic acid molecularly imprinted magnetic microporous organic network material for selectively enriching ganoderic acid substances, and belongs to the field of material preparation. The ganoderic acid molecularly imprinted magnetic microporous organic network material with large specific surface area, good selectivity and high adsorption capacity is prepared by a simple one-pot method. The material contains rich delocalized pi bonds, carboxyl groups, amino groups and specific hydrogen bond interaction sites, and can generate relatively strong hydrogen bond interaction and pi-pi interaction with ganoderic acid substances containing active sites such as steroidal rings, hydroxyl groups and carbonyl groups, so that an enhanced enrichment effect is achieved. The material is used as an adsorbent of a magnetic solid-phase extraction method and is used for high-selectivity enrichment and high-sensitivity detection of ganoderic acid substances.

This invention relates to the technical field of detecting active ingredients in Ganoderma lucidum and shiitake mushroom oral liquid, and provides a method for simultaneously detecting ergothioneine and ganoderic acid A in Ganoderma lucidum and shiitake mushroom oral liquid, comprising the following steps: detecting Ganoderma lucidum and shiitake mushroom oral liquid using high performance liquid chromatography (HPLC); the HPLC column used is a JADE-PAK NH2 column, the column temperature is 30-40℃, the detector is an ultraviolet detector, and the detection wavelength is 252-256nm; the mobile phase includes mobile phase A and mobile phase B, mobile phase A is an acetonitrile solution, mobile phase B is a 0.1% (V / V) aqueous solution of acetic acid, the volume ratio of mobile phase A to mobile phase B is (74-76):(24-26), and the flow rate of the mobile phase is 0.9-1.1 mL·min. ‑1 This invention utilizes a JADE-PAK NH2 amino column for the detection of Ganoderma lucidum and shiitake mushroom oral liquid, and through optimization of chromatographic conditions, enables accurate and rapid simultaneous determination of the contents of ganoderic acid A and ergothioneine in Ganoderma lucidum and shiitake mushroom oral liquid.

Use of ganoderic acid A in the preparation of a product for preventing and / or treating non-alcoholic fatty liver disease. Ganoderic acid A can regulate bile acid reabsorption in C57BL / 6J mice induced by a high-fat diet, and reduce the absorption of triglycerides and cholesterol. Ganoderic acid A can also enhance the expression of the gene of cholesterol 7α-hydroxylase, a key enzyme for liver cholesterol decomposition, thereby promoting the conversion of liver cholesterol into bile acid, and alleviating the accumulation of liver cholesterol. Ganoderic acid A has a significant preventive and ameliorative effect on non-alcoholic fatty liver disease induced by a high-fat diet by means of regulating bile acid metabolism, inhibiting lipid absorption, and reducing liver lipid accumulation. Therefore, ganoderic acid A can be used as a health care product, a functional product, or a drug for preventing and treating non-alcoholic fatty liver disease.

The invention discloses a novel oil-soluble micelle preparation. The component A comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, cardiolipin, cephalin and dipalmitoyl phosphatidylcholine, and the component B comprises lecithin, soya bean lecithin, egg yolk lecithin, 1-palmitoyl-2-oleoyl lecithin, phosphatidylserine, phosphatidylinositol, phosphatidyl glycerol, phosphatidylcholine, cephalin and dipalmitoyl phosphatidylcholine; one or more of dipalmitoyl phosphatidyl ethanolamine and dipalmitoyl phosphatidyl ethanolamine; the component B comprises a component B1 and a component B2, and the component B1 comprises one or more of phytosterol, cholesterol, ergosterol, protopanoxadiol, protopanaxatriol, ganoderic acid, phytol, isophytol, retinol, andrographolide, paclitaxel, artemisinin and bisabolol; and the component B2 is prepared from one or more of 1, 2-hexanediol, ethylhexylglycerin, cyclohexyl glycerin, absolute ethyl alcohol and isosorbide dimethyl ether. The key point of the invention is to provide a low-cost formula and a low-cost preparation method for preparing the oil-soluble micelle preparation.

The present application relates to a bacillus velezensis strain JZ01, a microbial agent containing the same and application thereof. The bacillus velezensis strain JZ01 can efficiently antagonize the pathogen of cucumber brown spot and effectively kill root-knot nematodes. Further, the present application also develops a synergist of the strain. It is found that trigonelline can be used as a synergist to significantly increase the efficacy of the strain against the pathogen of cucumber brown spot, and ganoderic acid A can enhance the efficacy of the strain in killing root-knot nematodes, so that a more efficient compound microbial agent can be developed. In addition, the bacillus velezensis strain and the microbial agent containing the same are microbial agents, which are safe and environmentally friendly, and therefore have high industrial value and application prospect.

The application provides preparation and application of a PROTAC degrading agent, and relates to the field of medicines.The ganoderic acid A-PROTAC compound with degrading activity provided by the application takes ganoderic acid A as raw material, retains the structural skeleton of ganoderic acid A, and is connected with E3 ubiquitin ligase Cereblon (CRBN) or VHL ligand by using different lengths of fatty chains or polyethylene glycol (PEG) chains to obtain ganoderic acid A derivatives GAA C1-C10 and V1-V10.The ganoderic acid A derivative with novel antitumor effect and the like is synthesized by a simple synthesis method.The ganoderic acid A derivative has the structure shown in the following general formula I.

The invention relates to the technical field of food and beverage development, in particular to a cherry sleep-aiding beverage and a preparation method thereof. The natural components of the lucid ganoderma, the spina date seeds and the lavandula angustifolia, the aminobutyric acid and the theanine are added, so that a basis is mainly provided for the sleep-aiding function of the cherry sleep-aiding drink; meanwhile, medium-chain triglyceride, thiamine hydrochloride, propylene glycol alginate, lysine and magnesium carbonate are introduced, so that the lucid ganoderma, the spina date seeds, the lavandula angustifolia, the aminobutyric acid and the theanine stably exist in the cherry sleep-aiding beverage, and the possible chemical reaction process with other components in the storage process is avoided; the function weakening and even disappearance caused by interference of other components can be avoided, and the sleep aiding function can be enhanced; the cherry concentrated solution, the sodium citrate, the vitamin C and the pectin are introduced, so that a cherry flavor and a stable beverage system are obtained, and the uniformity and the stability of each component are ensured.

The invention relates to the technical field of meat product processing, and particularly discloses a processing method of dried ganoderma lucidum meat slices. Comprising the following steps: stirring sliced pig hind leg meat, a lucid ganoderma water extract (dry lucid ganoderma: water = 100g: 1500ml, decoction and filtration) and auxiliary materials under the vacuum degree of 0.08-0.09 MPa for 10-15 minutes, standing at 4-8 DEG C for 1 hour, and driving by utilizing negative pressure gap expansion and osmotic pressure to enable the penetration depth of active ingredients to be gt; 500 [mu] m; dehydrating at 80 + / -2 DEG C for 8 hours (the water content is less than or equal to 30%), then instantly baking at 100-150 DEG C for 5-6 minutes, and carrying out hot-press shaping, so that the retention rate of ganoderic acid A is more than or equal to 70 The compound natural perfume (the ratio of licorice powder to star anise powder is 1: (2-3)) masks bitter taste, D-sodium erythorbate and sodium diacetate replace chemical preservatives, the water activity of the finished product is smaller than or equal to 0.75, and the shelf life is larger than or equal to 12 months. According to the invention, the technical bottleneck of difficulty in thermal degradation and permeation of ganoderma lucidum components is broken through, and the industrial problem of'thermal damage-permeation resistance-flavor conflict 'is solved on the molecular scale through an active component targeted delivery system (vacuum permeation and carrier wrapping) and a staged precise temperature control process; and the functional ganoderma lucidum dried meat slices with high activity retention rate, large penetration depth and good flavor harmony are produced.

This invention provides a composition for soothing nerves and improving sleep quality, and its preparation method, relating to the fields of functional foods and neurohealth technologies. The preparation method uses birch water as a base, compounded with thirteen medicinal and edible herbs including Ganoderma lucidum, jujube seed, and Poria cocos, combined with compound probiotics such as *Lactobacillus plantarum* JYLP-326, casein peptides, yeast β-glucan, γ-aminobutyric acid, and tea theanine, and blended with pear, mulberry, and blueberry fruit and vegetable purees to harmonize taste and nutrition. The mixture is prepared into an oral polypeptide beverage through low-temperature extraction of traditional Chinese medicine, anaerobic fermentation with compound probiotics, multi-stage homogenization, and low-temperature sterilization. This invention employs a four-fold combined mechanism of traditional Chinese medicine—soothing the nerves, calming nerves, regulating the gut-brain axis, and nutritional repair—to synergistically soothe nerves, relieve anxiety, shorten sleep latency, prolong deep sleep duration, and improve sleep quality. It is melatonin-free, non-addictive, and has no side effects, making it suitable for long-term consumption by people with insomnia, anxiety, and sub-health conditions.

The application belongs to the technical field of pharmacotherapy, and particularly relates to application of ganoderic acid A in preparation of a medicine for preventing acute kidney injury caused by kidney ischemia-reperfusion. The ganoderic acid A can inhibit apoptosis, pyroptosis and necrosis in acute kidney injury induced by kidney ischemia-reperfusion, and reduce the levels of creatinine and urea nitrogen, which are kidney function indexes. The application first discovers that the ganoderic acid A has a protective effect on kidney ischemia-reperfusion, and the mechanism is related to inhibition of pan-apoptosis (PANoptosis) of renal tubular epithelial cells, which indicates that the ganoderic acid A has a prospect of developing into a medicine for preventing acute kidney injury caused by kidney ischemia-reperfusion.

The invention discloses a process for enriching and refining ganoderic acid in ganoderma lucidum sporocarp, which comprises the following steps of: (1) crushing and sieving the ganoderma lucidum sporocarp, enriching ganoderic acid by adopting a Soxhlet extraction method, centrifuging and freeze-drying to obtain a crude ganoderic acid extract; (2) adding an extracting agent into the ganoderic acid crude extract for extraction, concentrating the obtained extracting solution by using a rotary evaporator, and freeze-drying to obtain a ganoderic acid crude product; and (3) adding the ganoderic acid crude product obtained in the step (2) into ethanol for anti-solvent crystallization, and freeze-drying the obtained solid to obtain a ganoderic acid finished product. The purity of the extracted ganoderic acid is high (the liquid phase purity is gt, 98%), the conversion rate can reach 90% or above, the commodity value is improved, anti-solvent crystallization is used, the extracted ganoderic acid product is white crystals, the ultraviolet transmittance is increased to 91% from 20%, the ganoderic acid product can be stably stored in wine, and the appearance vision of a wine solution is not affected.

The present invention relates to a detection method for the total triterpene content in an unbroken wall ganoderma spore powder, belongs to the field of drug analysis, and includes: weighing the unbroken wall ganoderma spore powder into a glass homogenizer, adding an extractant to break the wall; adding an extractant to the broken wall ganoderma spore powder mixed solution for ultrasonic extraction, and then high-speed low-temperature centrifugation to obtain a supernatant; concentrating the supernatant to near dryness and then re-dissolving it with n-hexane to obtain a supernatant; using anhydrous sodium sulfate and activated alumina mixed chromatography column to remove impurities in the supernatant, collecting and constant volume to obtain a sample solution; taking a certain amount of sample solution and evaporating it, adding vanillin glacial acetic acid solution and perchloric acid for color development reaction, cooling and adding glacial acetic acid to stand, filtering to obtain a solution to be tested; using ganoderic acid A as a standard sample to prepare a standard curve, and obtaining the total triterpene content in the sample by an external standard method. The present invention has high accuracy, good reproducibility, and strong applicability, and provides powerful technical support for the industrial production quality control of total triterpenes in ganoderma spore powder.

The invention provides application of bHLH family genes in ganoderma lucidum in synthesis of ganoderic acid and a method, and belongs to the field of gene engineering. The invention provides a bHLH family gene in ganoderma lucidum, which comprises transcription factors bHLH5 and bHLH7, the nucleotide sequences of the transcription factors are respectively shown as SEQ ID NO.1 and SEQ ID NO.3, and the amino acid sequences of the transcription factors are respectively shown as SEQ ID NO.2 and SEQ ID NO.4. The transcription factor bHLH5 and the lucid ganoderma LSS gene are constructed on a recombinant vector and are introduced into cells, so that the expression of the lucid ganoderma LSS gene can be activated; the transcription factor bHLH7, the ganoderma lucidum SQS gene and the ganoderma lucidum SE gene are respectively constructed on a recombinant vector and are introduced into cells, so that the expression of the ganoderma lucidum SQS gene and the ganoderma lucidum SE gene can be respectively activated, and the content of ganoderic acid in ganoderma lucidum is increased.

The invention provides a composition and application thereof in preparation of a reagent for resisting skin aging. The composition is prepared from afzelin and ganoderic acid A. The method can solve the problem that in the prior art, methods and products for resisting skin aging have limitations, and is suitable for the field of skin aging resistance.

This utility model discloses an extraction and purification device for ganoderic acid, belonging to the field of medicinal material processing technology. It solves the problem that unmelted ganoderic acid particles easily accumulate on the surface of the filter membrane of existing devices, and the surface of the particles easily adsorbs ganoderic acid solution, leading to waste of ganoderic acid solution. The device includes a filter box with a cover fixedly installed on the top surface and a connecting pipe fixedly connected to the bottom surface of the filter box. The connecting pipe is connected to a preparative chromatography device. The filter box contains a filter assembly, which includes a motor, a filter cylinder, and a liquid inlet pipe. The filter cylinder is hollow inside and has a liquid inlet hole in the middle of the right end face. Ganoderic acid solution is added to the inside of the filter cylinder through the liquid inlet pipe. The motor drives the filter cylinder to rotate, which can throw out the ganoderic acid solution inside the filter cylinder and adhering to the ganoderic acid particles, so as to fully filter out the ganoderic acid solution and avoid waste of ganoderic acid solution.